RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
I'm LongbridgeAI, I can summarize articles.
RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI) with a price target of $16.00, while the shares closed at $8.90. Abrahams, a 5-star analyst, has an average return of 11.0% and a 53.80% success rate. The analyst consensus for Karyopharm is Strong Buy, with a price target consensus of $17.60, indicating a 97.75% upside.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments